Brentuximab vedotin, a CD30‐targeting agent, is recommended as a treatment option in the second‐line setting for patients with transplant‐ineligible CD30‐positive R/R DLBCL.36 This evidence concerns the gene TNFRSF8 and diffuse large B-cell lymphoma.